Pancreatic Cancer Research

ResearcherUniversity of LisbonActive in the last 2 years

Marilia L. Cravo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8309-4599; OpenAlex author ID A5065822684. Sources: ClinicalTrials.gov.

Their work

Papers
3 (first author 0, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2022: 1 paper, 1 trial · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. NK Cell Adoptive Transfer Suppresses Metastasis and Prolongs Survival in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-9082655/v1↗
  2. Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma-A New Tool for Molecular Profiling of KRAS Mutations in Tumor and Plasma Samples. Last author DOI 10.3390/cancers16203544↗
  3. Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. Co-author DOI 10.1136/gutjnl-2021-324994↗

Trials 1

  1. Combined Exercise and Nutritional Intervention in GI Cancer Patients Study director NCT05420259↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Inês A. Batista · 2 shared papers, 2022–2026 · strength 0.35
  2. Sónia A. Melo · 2 shared papers, 2022–2026 · strength 0.35
  3. Jorge Paulino · 1 shared paper, 2024 · strength 0.18
  4. Ana Catarina Bravo · 1 shared paper, 2024 · strength 0.18
  5. Carolina F. Ruivo · 1 shared paper, 2022 · strength 0.11
  6. Pedro Moutinho-Ribeiro · 1 shared paper, 2022 · strength 0.11
  7. Nuno Bastos · 1 shared paper, 2022 · strength 0.11
  8. Bárbara Adem · 1 shared paper, 2022 · strength 0.11
  9. Raghu Kalluri · 1 shared paper, 2022 · strength 0.11
  10. Guilherme Macedo · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.